290 related articles for article (PubMed ID: 34813053)
1. Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.
Melosky B; Kambartel K; Häntschel M; Bennetts M; Nickens DJ; Brinkmann J; Kayser A; Moran M; Cappuzzo F
Mol Diagn Ther; 2022 Jan; 26(1):7-18. PubMed ID: 34813053
[TBL] [Abstract][Full Text] [Related]
2. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by
Vadagam P; Waters D; Lee I; Chen J; Tian D; Near AM; Lyle D; Vanderpoel J
J Med Econ; 2024; 27(1):219-229. PubMed ID: 38269536
[TBL] [Abstract][Full Text] [Related]
3. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
[TBL] [Abstract][Full Text] [Related]
4. The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC).
Ramadhan HH; Taaban DF; Hassan JK
Asian Pac J Cancer Prev; 2021 Feb; 22(2):591-596. PubMed ID: 33639678
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.
Van Sanden S; Murton M; Bobrowska A; Rahhali N; Sermon J; Rodrigues B; Goff-Leggett D; Chouaid C; Sebastian M; Greystoke A
Target Oncol; 2022 Mar; 17(2):153-166. PubMed ID: 35226283
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
8. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
9. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.
John T; Taylor A; Wang H; Eichinger C; Freeman C; Ahn MJ
Cancer Epidemiol; 2022 Feb; 76():102080. PubMed ID: 34922050
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
[TBL] [Abstract][Full Text] [Related]
13. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Zhang Y; Wang Q; Han ZG; Shan L
Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
15. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A
Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
Burnett H; Emich H; Carroll C; Stapleton N; Mahadevia P; Li T
PLoS One; 2021; 16(3):e0247620. PubMed ID: 33684140
[TBL] [Abstract][Full Text] [Related]
19. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A; Vasudevan S
Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
[TBL] [Abstract][Full Text] [Related]
20. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.
Mayo-de-Las-Casas C; Jordana-Ariza N; Garzón-Ibañez M; Balada-Bel A; Bertrán-Alamillo J; Viteri-Ramírez S; Reguart N; Muñoz-Quintana MA; Lianes-Barragan P; Camps C; Jantús E; Remon-Massip J; Calabuig S; Aguiar D; Gil ML; Viñolas N; Santos-Rodríguez AK; Majem M; García-Peláez B; Villatoro S; Pérez-Rosado A; Monasterio JC; Ovalle E; Catalán MJ; Campos R; Morales-Espinosa D; Martínez-Bueno A; González-Cao M; González X; Moya-Horno I; Sosa AE; Karachaliou N; Rosell R; Molina-Vila MA
Ann Oncol; 2017 Sep; 28(9):2248-2255. PubMed ID: 28911086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
